T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CIM
1701
Chimera Investment
CIM
$991M
| $1.08M | ﹤0.01% |
22,653
+3,713
| +20% | +$175K |
|
1702
Curtiss-Wright
CW
$25.7B
| $1.08M | ﹤0.01% |
16,500
-1,600
| -9% | -$105K |
|
|
HME
1703
DELISTED
HOME PROPERTIES, INC
HME
| $1.08M | ﹤0.01% |
16,890
| – | – |
|
|
WOOF
1704
DELISTED
VCA Inc.
WOOF
| $1.07M | ﹤0.01% |
30,600
+5,000
| +20% | +$163K |
|
1705
World Kinect Corp
WKC
$1.86B
| $1.06M | ﹤0.01% |
21,600
| – | – |
|
1706
Brookdale Senior Living
BKD
$3.02B
| $1.06M | ﹤0.01% |
31,800
+4,100
| +15% | +$133K |
|
1707
Tidewater
TDW
$4.72B
| $1.06M | ﹤0.01% |
585
-43
| -7% | -$71.3K |
|
1708
The GEO Group
GEO
$4.02B
| $1.06M | ﹤0.01% |
44,426
| – | – |
|
|
BMR
1709
DELISTED
BIOMED REALTY TRUST INC
BMR
| $1.06M | ﹤0.01% |
48,400
| – | – |
|
1710
Group 1 Automotive
GPI
$3.12B
| $1.05M | ﹤0.01% |
12,500
| – | – |
|
|
UNS
1711
DELISTED
UNS ENERGY CORP COM
UNS
| $1.05M | ﹤0.01% |
17,350
| – | – |
|
|
HTD
1712
John Hancock Tax-Advantaged Dividend Income Fund
HTD
$907M
| $1.05M | ﹤0.01% |
50,000
| – | – |
|
|
PACW
1713
DELISTED
PacWest Bancorp
PACW
| $1.04M | ﹤0.01% |
24,185
+13,735
| +131% | +$572K |
|
1714
Enbridge
ENB
$111B
| $1.04M | ﹤0.01% |
21,900
-9,400
| -30% | -$445K |
|
|
FXCB
1715
DELISTED
FOX CHASE BANCORP INC COM STK (MD)
FXCB
| $1.03M | ﹤0.01% |
61,000
| – | – |
|
|
TIVO
1716
DELISTED
Tivo Inc
TIVO
| $1.03M | ﹤0.01% |
42,833
| – | – |
|
1717
Portland General Electric
POR
$5.96B
| $1.02M | ﹤0.01% |
29,400
+4,000
| +16% | +$132K |
|
1718
Crane NXT
CXT
$2.97B
| $1.01M | ﹤0.01% |
39,272
| – | – |
|
1719
KBR
KBR
$4.85B
| $1.01M | ﹤0.01% |
42,400
+3,900
| +10% | +$97.8K |
|
|
VVC
1720
DELISTED
Vectren Corporation
VVC
| $997K | ﹤0.01% |
23,449
| – | – |
|
1721
Westlake Corp
WLK
$10.2B
| $992K | ﹤0.01% |
11,842
+1,000
| +9% | +$74.9K |
|
1722
Spire
SR
$4.89B
| $986K | ﹤0.01% |
20,310
+4,600
| +29% | +$215K |
|
1723
New Jersey Resources
NJR
$5.65B
| $982K | ﹤0.01% |
34,350
+2,600
| +8% | +$67.6K |
|
1724
Allison Transmission
ALSN
$10.4B
| $980K | ﹤0.01% |
31,500
+10,900
| +53% | +$329K |
|
|
UIL
1725
DELISTED
UIL HOLDINGS
UIL
| $975K | ﹤0.01% |
25,199
+3,200
| +15% | +$117K |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.